Skip to content
Our Company
Culture and Values
Leadership
Corporate Impact
Environmental, Social, and Governance
Product Donations
Charitable Giving
CME and Research Grants
Careers
Open Roles
Life at Emergent
Locations
Our Focus
Biological Threats
Opioid Crisis
Manufacturing Partnerships
Our Science
Pipeline
Our Products
Product and Medical Inquiries
Latest
Press Releases
Blog
Podcast
Media Statements
Media Resources
Investors
FOLLOW US
Press Releases
June 19, 2009
Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington
...
Read More
June 15, 2009
Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year
...
Read More
June 11, 2009
Emergent BioSolutions Meets With FDA To Review Regulatory Strategy for Recombinant Anthrax Vaccine
...
Read More
June 10, 2009
Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years
...
Read More
May 26, 2009
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
...
Read More
May 20, 2009
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern
...
Read More
May 13, 2009
Emergent BioSolutions Submits to FDA Development Plan Required of Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract with HHS
...
Read More
May 8, 2009
Emergent BioSolutions Launches BioThrax.com, an Educational Website about BioThrax (Anthrax Vaccine Adsorbed) and Anthrax Disease
...
Read More
May 8, 2009
Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington
...
Read More
May 7, 2009
Emergent BioSolutions Reports Financial Results for First Quarter 2009
...
Read More
May 5, 2009
Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vaccine Candidate Using EB66(R) Cell Line
...
Read More
May 5, 2009
Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX(R) Cell Line
...
Read More
1
2
…
48
49
50
…
58
59
